Looking to Partner with the World CNS Series?
Following a year of significant pharma acquisitions, approvals of transformative first-in-class drugs, and a surge in financial backing to bolster innovation across new targets and preclinical pipelines, 2026 is set to continue this momentum, with more companies prioritising neuroscience drug development than ever before.
If you offer relevant capabilities in this space and would like to align your brand with the CNS community, contact us to promote your expertise through a bespoke commercial partnership package.
Having trouble downloading the brochure? Let us know and we’ll email it to you instead.
Download Your Copy of the Sponsorship Prospectus
Explore the Agenda
Gain targeted insight into CNS oligonucleotide development, from BBB delivery and conjugation chemistry to translational modelling and clinical learning.
Partner With Us
Position your organisation at the centre of Europe’s CNS oligonucleotide ecosystem as it rapidly scales.
Join Biopharma Experts
Connect with senior CNS, RNA, and oligo leaders shaping the future of RNA-targeted neurological therapies.